Merck and Eisai to Present P-III Study (CLEAR) Results of Keytruda + Lenvima as 1L Treatment for Advanced Renal Cell Carcinoma at ASCO 2023
Shots:
- The final pre-specified OS analysis results from the P-III CLEAR (Study 307)/(KEYNOTE-581) trial evaluating Keytruda (200mg, IV, q3w for ~24mos.) + Lenvima (20mg, qd) vs sunitinib in a ratio (1:1:1) in 1069 patients
- The results showed that the patients maintained a clinical OS benefit after 4yrs. of follow-up, 21% reduction in risk of death, 24 & 36mos. estimated OS rates (80.4% & 66.4%) for Keytruda + Lenvima vs (69.6% & 60.2%) for sunitinib
- The safety profile was consistent with the primary analysis, 53% reduction in risk of disease progression or death with an m-PFS (23.9 vs 9.2mos.); ORR (71.3% vs 36.7%), CR rate (18.3% vs 4.8%) with no new safety signals & grade ≥3 TRAE (74.1% vs 60.3%)
Ref: Businesswire | Image: Merck
Related News:- Merck and Eisai Highlighted Update on P-III Trials (LEAP-003) and (LEAP-017) of Keytruda (pembrolizumab) + Lenvima (lenvatinib)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
